MD Anderson
VolitionRx, MD Anderson Cancer Center Partner to Study Cancer Patients With Sepsis
The study will use Volition's CE-marked Nu.Q NETs test to evaluate the role of neutrophil extracellular traps in cancer patients with sepsis.
MD Anderson, BostonGene Ink Collaboration to Develop Cancer Diagnostics
The partners will validate therapeutically actionable cancer biomarker targets and develop multiple tests from this research.
Nucleix, MD Anderson Partner on Methylation-Based Lung Cancer Dx Tests
The collaborators will initially evaluate methylation markers that they believe are important for characterizing lung cancer subtypes.
Adaptive Biotechnologies Prepares to Launch T Cell-Based COVID-19 Test
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
TargetCancer Foundation Initiates Precision Medicine Study for Rare Cancers
TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.
Nov 10, 2016